Leadership Team

Shaun R. Bagai

Chief Executive Officer

Mr. Bagai has served as our Chief Executive Officer and director since June 2014. Prior to joining us, Mr. Bagai led Global Market Development for HeartFlow, Inc. from 2011 to 2014, which included directing Japanese market research, regulatory/payer collaboration, and Key Opinion Leader development to create value resulting in a company investment to form HeartFlow-Japan. During his tenure at HeartFlow, he successfully orchestrated their largest clinical trial to date and contracted HeartFlow’s first global customers. In addition, Mr. Bagai has launched innovative technologies into regional and global marketplaces in both large corporations and growth-phase novel technology companies. He was instrumental in developing the European market for renal denervation for the treatment of hypertension leading to the acquisition of the first renal denervation company — Ardian, Inc. by Medtronic in 2011. Mr. Bagai is a graduate from the University of California, Santa Barbara with a BSc. in Biology/Pre-Med.

Ramtin Agah, MD

Chief Medical Officer, Founder

Dr. Agah has served as our Chief Medical Officer and Co-Founder since December 2009, and as Chairman of the Board since May 2018. Dr. Agah is currently an Interventional Cardiologist at El Camino Hospital, Mountain View, a role he began in September 2005. He also has acted as a physician consultant for Abbott Vascular since July 2012. Previously, Dr. Agah was an Assistant Professor of Internal Medicine with the Division of Cardiology, University of Utah. Dr. Agah completed a Fellowship in Interventional Cardiology with Cleveland Clinic Foundation, a Residency in Internal Medicine with Baylor College of Medicine and a Fellowship in Cardiology with University of California, San Francisco. He received his MD from the University of Texas Southwestern Medical School.

Mark Voll

Chief Financial Officer

Mark Voll is a seasoned financial executive with more than three decades of leadership experience in the semiconductor and high‑technology sectors. Throughout his career, he has earned a reputation as a trusted financial leader adept at guiding high‑growth companies through pivotal transitions, including IPOs, mergers, acquisitions, and large‑scale operational expansion. Mr.Voll has successfully guided companies through initial public offerings and subsequent exits, including Techwell, Inc. (IPO in 2006, acquired by Intersil in 2010), Montage Technology (IPO in 2013, acquired by PDSTI in 2014), and Aquantia Corporation (IPO in 2017, acquired by Marvell Technology in 2019). He holds a Bachelor of Science in Accounting from Providence College.

Leesa Gentry

Chief Clinical Officer

Ms. Gentry brings 29 years of experience focused on improving clinical research programs in Contract Research Organization (CRO), pharmaceutical, and biotech industries. Past employers include IQVIA (Quintiles), PPD, OmnicareCR and Otsuka. Prior to RenovoRx, she was Senior Vice President (SVP) of Clinical Operations at Evotec. (NASDAQ: EVO). At PPD, Ms. Gentry was Global Project Manager and Senior Research Specialist for Clinical Systems where her team developed one of the pharmaceutical industry’s first clinical trial management systems.

At Omnicare, Ms. Gentry grew the clinical research site network within long-term care; her work was featured in the Good Clinical Practice Journal. During her tenure at Otsuka, Ms. Gentry developed novel methods for improved, streamlined trial implementation in clinical operations, data management and third-party collaboration. Her work on registration trial implementation within resource-constrained environments was featured in the Bulletin of the World Health Organization. Ms. Gentry holds a B.A. in Psychology and M.S. in Gerontology from the University of Central Missouri, and an M.A. of Psychology from the University of Mary Hardin-Baylor.

Tom Kelly

Vice President of Quality and Operations

Mr. Kelly is Vice President of Quality and Operations and brings extensive leadership experience in the medical device industry. He specializes in organizational development and new product introduction and has successfully guided products and teams from early-stage startups through commercialization, acquisition, and post-acquisition integration. His career spans cardiovascular technologies at Perclose/Abbott Vascular, Cierra, Arstasis, and Tioga Cardiovascular; orthopedics at Stryker; ophthalmology at ForSight Vision4/Genentech; and women’s health at AEGEA/CooperSurgical. Mr. Kelly holds a Bachelor of Science in Manufacturing Engineering from Oregon State University.

Ronald B. Kocak, CPA

Vice President of Finance and Controller

Mr. Kocak is a seasoned financial reporting and accounting professional with extensive public company experience in the life sciences industry. Mr. Kocak has served as RenovoRx’s interim controller in a consulting capacity since October 2021. Prior to joining RenovoRx, Mr. Kocak was Controller and Senior Director of Finance at Sensei Biotherapeutics, Inc., where he successfully led the finance and accounting activities, including the IT operations. He holds a Bachelor of Science in accounting from Duquesne University and a CPA license in the Commonwealth of Virginia. Mr. Kocak is also a member of the American Institute of Certified Public Accountants and Association of Bioscience Financial Officers, and a Chartered Global Management Accountant.